Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cannabix stock rises on robust alcohol breathalyzer potential

Trevor Abes , The Market Online
0 Comments| November 7, 2023

{{labelSign}}  Favorites
{{errorMessage}}

  • Cannabix (CSE:BLO), a microcap tech stock, is nearing commercialization of its Contactless Alcohol Breathalyzer (CAB) wall-mounted device after successful preliminary third-party testing
  • Interest from U.S. and Australian organizations has prompted Cannabix to begin to establish distribution in these major markets
  • Cannabix Technologies develops marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories
  • Cannabix Technologies stock (CSE:BLO) has fallen by approximately 85 per cent since 2018

Cannabix (CSE:BLO), a microcap tech stock, is nearing commercialization of its Contactless Alcohol Breathalyzer (CAB) wall-mounted device after successful preliminary third-party testing.

The CAB assesses user sobriety in contactless or straw mode while confirming identity and attendance. Blood alcohol content readings can be sent in real-time via text message, e-mail and through dedicated company portals. The CAB also offers simplified calibration through modular cartridges, which save on costly and time-consuming visits from technicians.

Testing by QAI Laboratories in British Columbia, an accredited lab for electrical safety evaluations and certification in the United States and Canada, included electromagnetic compatibility, emissions, immunity and vibration. Pilot testing began in March 2023 with positive performance over 700 breath samples taken thus far.

Interest from U.S. and Australian organizations has prompted Cannabix to consult with a distributor and vendor of alcohol devices in Australia, as well as take initial steps to build distribution relationships with U.S. alcohol device vendors.

The CAB’s target market centres on small to medium-sized enterprises in construction, production, oil and gas, mining, agriculture, forestry, warehousing and transport. Potential applications include random testing, start-of-shift testing, pre-employment testing, return-to-work testing, post-incident testing, reasonable cause testing, pre-promotion testing, and the 24/7 Sobriety Program in the U.S., which seeks to reduce re-arrests for those previously convicted of driving under the influence of drugs or alcohol through daily breath testing.

The company is preparing the CAB for international alcohol standards testing and will be selecting a new product name in the coming weeks, followed by new product branding.

The news follows confirmation that Cannabix’s marijuana breathalyzer technology can quantify delta-9 THC levels from smoking and edibles, opening up innumerable commercial applications across law enforcement, government and industry.

Cannabix Technologies develops marijuana and alcohol breathalyzer technologies for law enforcement, workplaces and laboratories.

Cannabix Technologies stock (CSE:BLO) is up by 8.7 per cent trading at C$0.25 per share as of 9:56 am ET. The stock has fallen by approximately 85 per cent since 2018.

Join the discussion: Find out what everybody’s saying about this Canadian cannabis technology stock on the Cannabix Technologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.




{{labelSign}}  Favorites
{{errorMessage}}